Cixutumumab: Anti-CD221 human monoclonal antibody angiogenesis inhibitor oncolytic

E. K. Rowinsky, J. D. Schwartz, N. Zojwalla, H. Youssoufian, F. Fox, P. Pultar, D. L. Ludwig

Research output: Contribution to journalReview articlepeer-review

Fingerprint

Dive into the research topics of 'Cixutumumab: Anti-CD221 human monoclonal antibody angiogenesis inhibitor oncolytic'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology